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A functional polymorphism within butyrophilin-like 2 (BTNL2) gene has been described as
a potential risk factor for sarcoidosis. The association between chronicity and the rs2076530
SNP A allele has also been reported.
This study evaluates the BTNL2 rs2076530 G/A allele associations with sarcoidosis suscepti-
bility and disease evolution in a Portuguese cohort of patients.
A case-control study of 151 patients and 150 controls was performed. Allele frequencies
were compared with Chi-square test in a univariate analysis and with logistic regression in
a multivariate analysis.
BTNL2 rs206530 A allele frequencies were significantly higher in sarcoidosis with no linkage
disequilibrium with HLA-DRB1 alleles, except in the subgroup of patients with Lo¨fgren syndrome
where the determinant allele was HLA-DRB1*03. TheA allelewas also increased in thosewith iso-
lated thoracic disease, with no differences regarding radiological stages or disease evolution.
HLA-DRB1*03, besides the association with Lo¨fgren syndrome was significantly related with
disease resolution. Our data confirms the association ofBTNL2 rs2076530 A allelewith sarcoidosis
susceptibility in a Portuguese population. We found independent genetic risk factors in clinically
distinct disease phenotypes: BTNL2 rs2076530 A allele in patients without Lo¨fgren syndrome or
with isolated thoracic disease, and HLA-DRB1*03 in Lo¨fgren syndrome or disease resolution.
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Sarcoidosis is a multiorgan granulomatous inflammatory
disease of unknown etiology, characterized by activation of
macrophages and CD4þ T cells and the formation of non-
caseating granulomas, predominantly in the lungs and lymph
nodes.1,2 An underlying interaction between genetic factors
and unknown environmental factors is a widely accepted
hypothesis for the pathogenesis of sarcoidosis.3,4 Familiar
clustering, the increased risk of relatives to develop
sarcoidosis, and different clinical presentations related to
distinct ethnic groups, support the role of genetic factors in
sarcoidosis susceptibility and heterogeneity.5,6
Family-based and case control studies have consistently
shown an association between Human Leukocyte Antigen
(HLA) haplotypes and sarcoidosis, regarding both disease
susceptibility and phenotype expression.7,8 However due to
thehigh rangeof linkagedisequilibrium (LD)within themajor
histocompatibility complex (MHC) it remains unclear
whether the HLA genes directly determine the susceptibility
or the associations are due to other genes in linkage with this
region.9,10 This is the case of butyrophilin-like 2 (BTNL2)
gene, a member of the immunoglobulin superfamily located
at the junction of the HLA class II and class III regions.11,12
Valentonyte et al. reported for the first time a novel
association with a truncating single nucleotide polymorphism
(SNP) rs2076530 (G/ A) of theBTNL2 gene, independently of
the HLA sarcoidosis risk alleles.11 BTNL2 seems to have a role
in the modulation of costimulatory receptors involved in T-
cell responses, on the basis of its amino acid homology to the
CD80/CD86 family of costimulatory proteins.13,14 As a conse-
quence,dysfunctionof theBTNL2protein could impair normal
T-cell regulation and response to antigens. Following the
initial report, other studies of BTNL2 polymorphisms and
sarcoidosis generated conflicting results in populations from
different geographic areas or different disease pheno-
types.15,16 On theother hand,whetherBTNL2associations are
independent of HLA-DRB1 alleles remains to be elucidated, in
view of contradictory data so far.11,16e19
Our purpose was to evaluate BTNL2 rs2076530 G/A allele
as a putative genetic risk for sarcoidosis in a Portuguese
population, before and after stratification of clinically
distinct disease phenotypes and evolution. Given the vari-
ability of the published data from diverse ethnic groups, an




For a case-control study with 1:1 ratio, a type 1 error rate of
5%, an 80% of power to detect a modest genotype odds ratio
of 1.4 for disease susceptibility, we estimated a sample size
with 123 patients and 123 controls. We included a total of
151 unrelated Caucasian patients from the north region of
Portugal (mean age 38.0  4.2 years, 57% women) and 150
controls. All patients had thoracic sarcoidosis, as deter-
mined by symptoms, radiology and pulmonary function
tests, supported by the evidence of non-caseating epitheloid
cell granuloma in biopsy specimens in 66%. All subjectswithout histological confirmation fulfilled the ERS/ATS/
WASOG statement criteria,2 namely compatible clinical and
radiographic features, a bronchoalveolar lavage fluid (BALF)
lymphocyte CD4/CD8 > 4.0, and a 2 years observation
period to exclude other medical conditions. Lo¨fgren’s
syndrome (LS) was defined as bilateral hilar lymphadenop-
athy, fever, ankle arthralgia and erythema nodosum.1e3
Thoracic involvement was classified according with Scad-
ding criteria at the time of diagnosis (stage 0-no thoracic
involvement, stage I-adenopathies without lung involve-
ment, stage II-adenopathies and lung involvement, stage III-
only lung involvement, IV-lung fibrosis).20 Disease resolution
was considered when a disappearance of symptoms,
normalization of chest X-ray and pulmonary function tests
occurred within 2 years after diagnosis.18,19,21 A control
group included 150 unrelated and healthy bone marrow
donors, randomly recruited from the same geographic region
and from the same ethnic background. They had a mean age
of 51.9  14.5 years and 51% were women, no history of lung
disease, respiratory symptoms or other disease by chest
radiography or laboratory blood tests. Written consent was
obtained from all subjects, and the study approved by our
hospital Ethics Committee.Genotyping
DNA from patients and controls was obtained from periph-
eral blood using standard methods. Samples were geno-
typed for the BTNL2 G / A transition of rs2076530 using
a TaqMan SNP genotyping assay (Applied Biosystems, Foster
City, CA, USA). Minor groove binding probes were labeled
with the fluorescent dyes VIC and FAM, respectively. Poly-
merase chain reaction (PCR) was carried in a total reaction
volume of 12.5 ml with TaqMan SNP Genotyping assay 1x,
TaqMan Genotyping Master Mix 1x and 20 ng of genomic
DNA. The amplification protocol included a denaturation at
95 C for 10 min, followed by 40 cycles of denaturation at
92 C for 15 s and annealing and extension at 60 C for
1 min. After PCR, the genotype was determined by allelic-
specific fluorescence on the ABI PRIM 7000 Sequence
Detection Systems and SDS 1.1 software for allelic
discrimination (Applied Biosystems, Foster City, CA, USA).
DNA samples were also genotyped for HLA-A, B, Cw, DRB1
and DQB1 by PCR-Sequence Specific Oligonucleotides (PCR-
SSO) with Luminex technology (Tepnel Lifecodes Kits,
Stamford). DNA amplification was carried in a total volume
of 25 ml with 7.5 ml of Master Mix specific for each locus,
1.25 U of GoTaq Hot Start Polymerase (Promega, Madison
WI) and 50 ng of genomic DNA. PCR was run with the
program: 5 min at 95 C, followed by 8 cycles of 95 C 30s,
60 C 45s, 72 C 45s, with an increment of 32 cycles of 95 C
30s, 63 C 45s, 72 C 45s and a final extension hold of 72 C
for 15 min. After DNA amplification, 2.5 ml of PCR product
was mixed with 7.5 ml of pre-warmed Luminex probes (58 C)
and hybridized with the following protocol: 97 C for 5 min,
47 C for 30 min and 56 C for 10 min, prior to Luminex
reading, the hybridization stage stopped at 56 C with 100 ml
of a dilution solution combined with 0.4 ml of Streptavidin-PE
(Tepnel Lifecodes, Stamford). HLA typing was analyzed with
the software Quicktype LifeMatch v2.5 (Tepnel Lifecodes).
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Allelic and genotypic distributions were statistically
analyzed with the c2-test (or Fisher exact test when
appropriate) in univariate analysis and with logistic regres-
sion in multivariate analysis. Relative Risks or Odds ratios
(OR) and their 95% confidence intervals (95% CIs) were
calculated as association measures. The software used was
the Statcalc program (EpiInfo 2002, Centers for Disease
Control and Prevention, Atlanta, GA, USA). Regression
analyses where performed in SPSS v13 statistical software. p
Values less than 0.05 were considered statistically signifi-
cant. p Values where corrected (pc) for multiple compari-
sons using Bonferroni method. HLA data and BTNL2
haplotypes were analyzed by carriage frequency, while
BTNL2 allele’s data by allele frequency unless otherwise
stated. Due to the strong LD between many HLA alleles and
BTNL2, logistic regression analysis was performed to deter-
mine the potential for confounding and effect modification
of BTNL2 allelic in relation to HLA class II risk alleles. For
haplotype analysis, pairwise LD measures were investigated
and HLA-DRB1*-DQB1*-BTNL2 haplotypes constructed with
the expectation-maximization (EM) algorithm implemented
in Arlequin software.22 LD between selected pairs of loci was
tested using a likelihood test for the significance of the
association between pairs of loci, where the likelihood of
the sample evaluated under the hypothesis of no association
between loci (linkage equilibrium) is compared to the like-
lihood of the sample when association is allowed. We tested
LD between two alleles from two different loci, constructing
a 2  2 contingence table with the individual (observed)
values cross-classified by level in the two different attri-
butes, i.e., two alleles from two different loci.Results
According with Scadding criteria 49 (32.4%) patients were in
stage I, 67 (44.3%) in stage II, 14 (9.2%) in stage III and 21
(13.9%) in stage IV. Sixty one (40.3%) patients presented
extra-thoracic disease, with skin and liver as the most
frequent involved structures, both with 21 (13.9%) patients.
Lo¨fgren’s syndrome was observed in 29 (19.2%) cases. A
consistent clinical course was established in 144 patients
(95.4%), 66 (43.7%) presenting disease resolution and 78
(51.7%) chronic forms; among these, 41 (52.6%) had chronic
stable and 37 (47.4%) progressive disease.Disease susceptibility
BTNL2 rs2076530 genotype frequencies and HLA allele
frequencies were in HardyeWeinberg equilibrium across
both studied populations, cases and controls. Genotype and
allele frequencies were similar to those reported for
Caucasians.23 When allele and genotype frequencies of
healthy controls and patients were compared, an associa-
tion of the BTNL2 rs2076530 polymorphism with sarcoidosis
was noted, with a significant increase of the rs2076530 A
allele frequency in the sarcoidosis group compared with
controls (65.2% vs 55.7%, ORZ 1.49, 95% CIZ [1.06; 2.10],
p Z 0.01) (Table 1). Association of BTNL2 rs2076530 AAgenotype with sarcoidosis risk was even stronger (44.4% vs
28.7%, OR Z 1.98, 95% CI Z [1.20; 3.29], p Z 0.004).
The HLA alleles associated positively with sarcoidosis on
univariate analysis were A*03, B*07, DRB1*14. Otherwise,
A*02, A*29, B*44, Cw*16, DRB1*07, DRB1*08 were statisti-
cally significant as protectors for the disease (Table 1).
However, only Cw*16 remains significantly associated with
sarcoidosis after Bonferroni correction for multiple
comparisons. Although degree of LD over the HLA genomic
region is high and variable,7,10 LD between rs2076530 A
allele and DRB1*14, an allele previously described in
sarcoidosis susceptibility,24,25 was not statistically signifi-
cant. To further evaluate the DRB1*14 allele effect on the
association between BTNL2 rs2076530 A allele and
sarcoidosis, multiple logistic regression was performed. The
rs2076530 AA genotype (OR Z 1.89, 95% CI Z [1.17; 3.06],
p Z 0.01) remained significantly associated with disease
risk. DRB1*14 allele was still overrepresented in the patient
group although not significantly so after adjusting for the
BTNL2 allele (ORZ 3.29, 95% CIZ [0.88; 12.21], pZ 0.08).
The effect modification was also tested in a regression
model with terms for the rs2076530 AA genotype, DRB1*14
allele and a cross-product interaction term. This interac-
tion did not reach statistical significance.Clinical presentation
When patients with (n Z 29, 19.2%) and without (n Z 114,
75.4%) Lo¨fgren’s syndrome were analyzed, we didn’t find
significant differences between BTNL2 rs2076530 A allele
frequencies (Table 2). The association found between
BTNL2 rs2076530 A allele and sarcoidosis was statistically
significant for both groups: Lo¨fgren’s syndrome (ORZ 2.09,
95% CI [1.88; 4.07], p Z 0.02); non Lo¨fgren’s syndrome
(OR Z 1.56, 95% CI [1.08; 2.27], p Z 0.01).
HLA-DRB1*03 allele was also strongly associated with
Lo¨fgren’s syndrome, both when compared with patients
without Lo¨fgren’s syndrome (RR Z 2.56; 95% CI Z [1.62;
4.06], pc < 0.01) or controls (OR Z 4.01, 95% CI Z [1.88;
8.56], pc < 0.01). HLA-DQB1*02 allele was also associated
with Lo¨fgren’s syndrome patients, but LD between DRB1*03
and DQB1*02 alleles was statistically significant (p < 0.001).
In a logistic regression model with HLA-DRB1*03, -DQB1*02
and rs2076530 A alleles, only DRB1*03 allele was signifi-
cantly associated with Lo¨fgren’s syndrome, when compared
with patients without Lo¨fgren’s syndrome.
The association of DRB1*14 allele with sarcoidosis was
only statistically significant for patients without Lo¨fgren’s
syndrome (OR Z 4.07, 95% CI Z [1.0; 23.6]) with no
statistically significant LD with BTNL2 rs3076530 allele
(p Z 0.22), so this SNP remains associated with non-
Lo¨fgren’s syndrome, after DRB1 adjustment.
Comparison of rs206530 allele frequencies between
patients with and without extra-thoracic involvement
showed increased frequencies of A allele in those with
isolated thoracic disease (71.5% vs 56.8%, RRZ 1.32; 95% CI
for RR Z [1.05; 1.66]; p Z 0.01), although with no signifi-
cant differences among the radiological stages (data not
shown). No differences were detected regarding HLA
alleles between patients with isolated thoracic disease and
those with extra-thoracic disease.
Table 1 BTNL2 and HLA alleles associated with sarcoidosis susceptibility.
Allele Sarcoidosis Controls p value pc OR 95% CI
n Z 302 (%)a n Z 300 (%)a
rs2076530 A 197 (65.2%) 167 (55.7%) 0.01 e 1.49 1.06e2.10
rs2076530 G 105 (34.8%) 133 (44.3%) 0.01 e 0.67 0.48e0.94
A*03 38 (12.6%) 23 (7.7%) 0.04 0.72 1.73 0.97e3.10
A*29 11 (3.6%) 23 (7.7%) 0.03 0.54 0.46 0.20e1.00
B*07 23 (7.6%) 11 (3.7%) 0.03 0.84 2.17 0.99e4.83
B*44 28 (9.3%) 52 (17.3%) 0.003 0.08 0.49 0.29e0.82
C*16 13 (4.3%) 34 (11.3%) 0.001 0.01 0.35 0.17e0.71
DRB1*07 33 (10.9%) 50 (16.7%) 0.04 0.52 0.61 0.37e1.01
DRB1*08 5 (1.7%) 17 (5.7%) 0.01 0.12 0.28 0.08e0.81
DRB1*14 11 (3.6%) 3 (1.0%) 0.03 0.39 3.74 0.97e21,06
a Allele frequencies; OR e Odds Ratio; CI e Confidence Interval; pc e corrected p-value for multiple comparisons.
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Comparison of rs206530 allele frequencies between chronic
patients and those who had disease resolution didn’t show
any statistically significant differences (Table 3). No
differences were also seen comparing patients with reso-
lution with those with chronic stable or progressive disease
(data not shown). Moreover, comparison between these
two groups of chronic patients didn’t found any differences
regarding BTNL2 rs2076530 A SNP (64.6% vs 62.2%,
RR Z 1.05; 95% CI for RR Z [0.77; 1.44]; p Z 0.75).
However, regarding HLA alleles, disease resolution was
significantly associated with DRB1*03 (RR Z 1.61; 95%
CI Z [1.23; 2.1]; p Z 0.004).Discussion
In this study, we evaluated a single nucleotide poly-
morphism of the BTNL2 gene, as a putative genetic risk
factor for sarcoidosis in a Portuguese population. The
significant increase of the BTNL2 rs2076530 A allele
observed, corroborates the role of this truncating SNP in
disease susceptibility. Analyzing the subgroup presenting
with Lo¨fgren’s syndrome, this association disappeared after
HLA class II allele adjustment, since the determinant allele
was HLA-DRB1*03; nevertheless, the association persists in
the subgroup of patients without Lo¨fgren syndrome even
after adjustment for HLA-DRB1. An increased frequency of
A allele was also noticed in those with isolated thoracic
disease, although with no differences regarding radiological
stages, disease resolution or a chronic course over at least 2
years of follow-up. HLA-DRB1*03 allele, besides itsTable 2 BTNL2 and HLA class II alleles associated with Lo¨fgren
Allele With LS Without LS
n Z 58 (%)a n Z 228 (%)a
rs2076530 A 42 (72.4%) 151 (66.2%)
DRB1*03 16 (27.6%) 21 (9.2%)
DRB1*04 1 (1.7%) 30 (13.2%)
DQB1*02 24 (41.4%) 42 (18.4%)
a Allele frequencies; RR e relative risk; CI e confidence interval; passociation with Lo¨fgren syndrome, was also significantly
related with disease resolution.
BTNL2 is a member of the butyrophilin-like molecules
(BTNLs) sharing structural homology with CD80/CD86 (B7)
family of costimulatory molecules, expressed on antigen-
presenting cells (APCs) and critical for effector immune
responses.12 BTNLs have a restricted expression in human
cells and BTNL2, along with some epithelial cells of the
mucosal barriers, is expressed on dendritic cells (spleen
and lymph nodes)13 and peripheral B cells,14 consistent with
a role in the modulation of APCs function. In fact, BTNL2
has been shown to inhibit T cell proliferation and IL-2
production, also diminishing the production of pro-
inflammatory cytokines in T cell cultures.12e14 The single
nucleotide polymorphism that we studied (rs2076530
G > A), results in a mutated BTNL2 gene leading to a trun-
cated protein and disruption of its membrane localiza-
tion.26 Although the precise functional implications of this
mutation has not been established,12 the putative inap-
propriate/inadequate membrane expression of a molecule
inducing a negative signal to T-lymphocytes, could result in
an uncontrolled high state of activation of T cells, a known
pathological feature of sarcoidosis.2,27,28
One possible limitation of our study is the number of
included cases. However, it represents the population
currently referred to our university hospital center, which
gives respiratory care to a total of 3 million inhabitants in
the North region of Portugal (a country with 9 million
inhabitants). This is a relatively homogeneous population
and our controls were from the same geographic and
genetic background. Another limitation concerns a sarcoid-
osis cohort in a tertiary care setting, potentially excluding
less sever forms. The majority (59.7%) of our patients had’s syndrome (LS).
p pc RR 95% CI
0.4 e 1.26 0.75e2.13
0.0002 0.003 2.56 1.62e4.06
0.01 0.13 0.14 0.02e1.01
0.0002 0.001 2.35 1.51e3.67
c e corrected p-value for multiple comparisons.
Table 3 BTNL2 and HLA class II alleles associated with disease outcome in sarcoidosis.
Allele Resolution Chronic p pc RR 95% CI
n Z 132 (%)a n Z 156 (%)a
rs2076530 A 91 (68.9%) 99 (63.5%) 0.32 e 1.14 0.87e1.51
DRB1*01 18 (13.6%) 10 (6.4%) 0.04 0.48 1.47 1.08; 2.00
DRB1*03 24 (18.2%) 11 (7.1%) 0.004 0.05 1.61 1.23e2.10
a Allele frequencies; RR e relative risk; CI e confidence interval; pc e corrected p-value for multiple comparisons.
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43% disease resolution, 26.4% chronic stable disease and
25.1% chronic progressive disease, which seems in accor-
dance with the usual presentations of Caucasians followed
in specialized care settings.1,2 Although not age matched to
the patients, our controls were unrelated healthy individ-
uals, recruited from the same geographic and ethnic
background. Their comparatively higher mean age gives
additional confidence, since a possible sarcoidosis diagnosis
in their life time will be less likely.
Several studies have been published in different pop-
ulations and ethnic groups, with different approaches
regarding clinical phenotyping or HLA allele’s adjust-
ment.11,15,16,29 Although with different conclusions, an
overall evaluation of the available data supports a role of
this SNP in the disease susceptibility. In our cohort there is
also an unquestionable statistical significant relation
between BTNL2 rs2076530 SNP and sarcoidosis suscepti-
bility. The consistency of these results is sustained by the
fact that no linkage disequilibrium was found with DRB1*
alleles, namely DRB1*14, previously described as a risk
allele in other sarcoidosis cohorts.24,25
Our findings are in accordance with the data from
Caucasian populations. Rybicki et al. found a strong asso-
ciation of the rs2076530 SNP with a white American cohort,
but not in African American patients, although a three-
locus haplotype that included rs2076530 was associated
with this population.15 This study also suggested an influ-
ence of race in this genetic risk as the association with
BTNL2 was independent of the HLA class II genes in whites
but interacted antagonistically in African Americans,
a population with greater genetic diversity. Valentonyte
et al. also found an association of the rs2076530 A allele
with predisposition to sarcoidosis in a white German pop-
ulation, with no apparent influence from HLA alleles.11
Milman et al. found the A allele and an AA genotype
significantly associated with sarcoidosis in a Danish pop-
ulation, although the degree of LD with DRB1 or DQB1 was
not considered.29
On the other hand, Spagnolo et al. found a significant
association between BTNL2 rs2076530 A allele on a cohort
of United Kingdom and Netherlands patients, but the
association disappeared after exclusion of Lo¨fgren
syndrome and adjusting for HLA-DRB1 alleles.16 Neither the
study of Valentonyte et al. nor Rybicki et al. stratified their
data according to Lo¨fgren’s syndrome,11,15 a genetically
and phenotypically different subset of patients character-
ized by an acute presentation and good prognosis.1,2,6 Our
results are somehow different from the British and Dutch
cohort studied by Spagnolo et al., since the BTNL2
rs2076530 SNP association was significant in the subgroup ofpatients without Lo¨fgren syndrome, while the association
with Lo¨fgren syndrome patients in a univariate analysis was
secondary to HLA-DRB1*03 allele. Both a different genetic
backgrounds and patient’s selection may account for these
discrepancies, as our patients were consecutively recruited
from a tertiary reference center, a cohort more similar to
the one reported by Valentonyte group.11 Otherwise, the
association of HLA-DRB1*03 with Lo¨fgren syndrome has
been described in several populations7,16,30e32 and
different DRB1*03 frequencies may even explain the rarity
of this clinical presentation in Japan and the higher prev-
alence in Scandinavian countries.6,33
Interestingly, associations between BTNL2 rs2076530 A
allele and a group of different diseases such as multiple
sclerosis, leprosy, type 1 diabetes, rheumatoid arthritis,
systemic lupus erythematosus or Graves disease, were
actually due to LD with other genes from this region,
namely with various HLA-DRB1 alleles, highlighting the
difficulty to allocate primary associations in this highly
dense gene area.10,12,16,29 Thus, there is an absolute
requirement for adjustment to HLA-DR alleles to every
significant result related with BTNL2 haplotypes, as we
performed in our study.
Regarding the different sarcoidosis phenotypes, we also
found a significant increase of BTNL2 A allele with isolated
thoracic involvement. To our knowledge, this association
has never been reported or addressed in previous studies,
although no differences were seen among the four radio-
logical Scadding stages, a finding also described by Spag-
nolo et al.16
Li et al. described for the first time an association
between BTNL2 rs2076530 A SNP and a chronic disease
course, in a German population.18 However no linkage
disequilibrium analysis to DRB1 alleles was carried out, and
the type of evolution of the chronic forms was not
accessed. Coudurier et al. described the pathogenic variant
of BTNL2 on both alleles (AA homozygote) in three related
patients, all with severe forms, although they also did not
address HLA-DR linkage.26 Collectively, these results do
suggest an association of the variant allele with more
severe cases with progression to fibrosis.
Generally we can consider three forms of evolution in
sarcoidosis: disease resolution, chronic stable and chronic
progressive disease (needing persistent therapeutic
intervention).19,34 In our cohort we stratified these
different outcomes with the hypothesis that they might be
related with different genetic risk factors. However, we
didn’t find any significant association between BTNL2 and
outcomes, neither with those who had disease resolution
nor with who become chronic. Moreover, no differences
between chronic stable or chronic progressive disease
1776 A. Morais et al.were found. On the other hand, disease resolution was
significantly associated with DRB1*03, an association also
seen in various Caucasian populations.30e32 In contrast
with our observations, Wijnen et al. described that BTNL2
rs2076530 variant allele was more frequent in patients
with chronic persistent (progressive) disease than chronic
non-persistent (stable) disease, independently from DRB1
allele’s influence.19 In their larger Dutch cohort, the A-
allele almost doubled the risk of a progressive course of
sarcoidosis.19
In conclusion, our study of a Portuguese sarcoidosis
cohort at a tertiary reference centre showed a significant
increase of the BTNL2 rs2076530 A allele frequency, with an
even stronger association to the BTNL2 rs2076530 AA
genotype, corroborating the role of this truncating SNP in
the genetic risk of sarcoidosis in our population. Taking in
account BTNL2 and HLA-DR linkage disequilibrium, we also
uncovered two independent genetic risk factors for
different clinical presentations of sarcoidosis: the BTNL2
rs2076530 A allele in patients without Lo¨fgren syndrome or
with isolated thoracic disease, and the HLA-DRB1*03 allele
in those presenting Lo¨fgren syndrome or disease resolution
within 2 years of follow-up. The immunogenetic base of
these associations deserves further investigation.Conflict of interest statement
The authors have no conflict of interest.References
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